Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2011

View Archived Issues

Sanofi profiles pipeline highlights of third quarter 2011

Almirall and BioFocus enter collaboration

Eisai develops novel lanosterol synthase inhibitor for HCV

Preclinical profile of Merck & Co.'s HCV NS5A inhibitor MK-4882 described

Achillion Pharmaceuticals describes second-generation NS5A inhibitors

Gilead and Tibotec finalize agreement on single-tablet HIV regimen

EB-1020 as a new approach to treat ADHD

Favorable preclinical profile of C-21191 supports development for pain, spasticity

AVI BioPharma enters collaborations for two new exon-skipping drugs

Midatech obtains Swiss approval to test insulin-coated gold nanoparticles

Patient recruitment commences in phase I study of MK-1439 for HIV-1 infection

Researchers in India disclose novel NO-releasing prodrugs

UCB offers review of third quarter 2011

Phase I LG-631 gene therapy trial initiated for brain cancer

PharmacoFore presents new enzyme-cleavable amphetamine prodrugs

Prosidion researchers prepare novel GPR119 receptor agonists/DPP IV inhibitors

Array BioPharma patents new tyrosine-protein kinase inhibitors

Genzyme and Cystic Fibrosis Foundation enter collaboration for new cystic fibrosis drugs

Novel tyrosine-protein kinase inhibitors synthesized by MethylGene

Phase I MTN-013/IPM 026 safety trial for HIV enters subject screening stage

Profectus BioSciences receives additional grant from PATH Malaria Vaccine Initiative

PharmaGap starts animal efficacy study of GAP-107B8

BioSante Pharmaceuticals reports results from LibiGel pharmacokinetic study

Athersys regains rights to MultiStem cardiovascular program

Bristol-Myers Squib seeks approval of new indication for Taxol in Japan

InSite Vision starts phase III study of AzaSite Plus and DexaSite for blepharitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...